GlassScriptPhysician profile
Olivia Smith Blackwell
NPI 1023075918
$15,541.89
in general payments reported to CMS, 2019-2025
38 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,920 · 2020: $1,059 · 2021: $2,806 · 2022: $2,139 · 2023: $2,518 · 2024: $2,407 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,614 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,613.88 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,816.17 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,683.62 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,017.97 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $898.07 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $673.84 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.66 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $645.44 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $637.69 | 2019-2025 | Repatha, Otezla, Tepezza |
| Esperion Therapeutics, INC. | $532.93 | 2020-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $526.99 | 2020-2021 | |
| Amarin Pharma, INC. | $476.55 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $413.06 | 2023-2025 | Nuzyra |
| Insulet Corporation | $384.95 | 2024-2025 | Omnipod, Omnipod |
| Exact Sciences Corporation | $365.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $338.73 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Smith Blackwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.